Viewing Study NCT00121381



Ignite Creation Date: 2024-05-05 @ 11:46 AM
Last Modification Date: 2024-10-26 @ 9:12 AM
Study NCT ID: NCT00121381
Status: COMPLETED
Last Update Posted: 2008-01-15
First Post: 2005-07-14

Brief Title: Pimecrolimus Cream 1 Plus Topical Corticosteroid in Patients 2-17 Years of Age With Severe Atopic Dermatitis
Sponsor: Novartis
Organization: Novartis

Study Overview

Official Title: Pimecrolimus Cream 1 Plus Topical Corticosteroid in Patients 2-17 Years of Age With Severe Atopic Dermatitis
Status: COMPLETED
Status Verified Date: 2008-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Atopic dermatitis also called eczema is characterized by redness papulation skin elevation and pruritus skin itching The active ingredient of pimecrolimus inhibits the T-cell activation These cells are involved in the inflammatory component of the disease This study will test the safety of pimecrolimus Cream 1 with topical corticosteroid treatment commonly used in eczema in patients with severe atopic dermatitis
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None